Log in
Enquire now
‌

US Patent 9528102 Proteoglycan degrading mutants for treatment of CNS

Patent 9528102 was granted and assigned to Acorda Therapeutics, Inc. on December, 2016 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc.
Current Assignee
Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc.
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9528102
Patent Inventor Names
Rohini D'Souza0
Anthony O. Caggiano0
Elliott A. Gruskin0
Gargi Roy0
Date of Patent
December 27, 2016
Patent Application Number
14188679
Date Filed
February 24, 2014
Patent Primary Examiner
‌
Rebecca Prouty
Patent abstract

The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9528102 Proteoglycan degrading mutants for treatment of CNS

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.